Clinical characteristics and risk factors of non-Candida fungaemia

BMC Infectious Diseases

Table 1 Clinical characteristics of non- Candida fungaemia infection

	C. neoformans(n = 6)	T. asahii(n = 4)	K. ohmeri(n = 1)
Co-morbidities^a	6 (100%)	4 (100%)	1 (100%)
Immunosuppressant therapy	4(66.7%)	2 (50.0%)	1 (100%)
Renal replacement therapy	2 (33.3%)	2 (50.0%)	1 (100%)
Colonisation by causative yeasts	4 (66.7%)	4 (100%)	1 (100%)
SOFA score, median (range)	9 (1–18)	8 (1–17)	20 (−)
In vitro-active antifungal agent	4 (66.7%)	1 (25.0%)	1 (100%)
30-day mortality	3 (50.0%)	3 (75.0%)	0 (0%)

SOFA: sequential organ failure assessment.
^a Co-morbidities of C. neoformans infection include acute respiratory distress syndrome, hepatitis C virus infection, post-living donor liver transplantation (LDLT), systemic lupus erythaematosus, and miliary tuberculosis. Co-morbidities of T. asahii infection include POEMS syndrome, liver cirrhosis, Bechet’s disease, and acute myeloid leukaemia. Co-morbidities of K. ohmeri infection include alcoholic liver cirrhosis and post-LDLT.

ISSN: 1471-2334